Teva, IBM to tackle new drugs, chronic diseases with AI 7wData

IBM and Teva Pharmaceutical Industries Ltd. said Wednesday they would significantly expand their existing global e-Health alliance with a focus on two key healthcare areas: the discovery of new treatment options and improving chronic disease management. Both projects will run on the IBM Watson Health Cloud, the two companies said in a statement. The IBM Watson Health Cloud is a health-data enabled platform-as-a-service which is designed to help healthcare organizations derive individualized insights and obtain a more complete picture of the many factors that can affect people's health based on machine learning. The expanded partnership underlines the increased convergence of drugs discovery and treatments with cognitive computing, which aims to improve and better target medication for patients, increase effectiveness and lower costs. The companies said the expanded cooperation envisages a new, three-year research collaboration to develop new technologies that will enable a systematic approach to help repurpose drugs and aid in the discovery of new uses for existing drugs, the joint statement said.